India, Sept. 3 -- Summit Therapeutics Inc. (SMMT) shares are currently trading at $16.24, up $1.64, or 11.23 percent on Thursday, likely supported by positive overall survival results from the Phase III HARMONi-2 study of ivonescimab in patients with locally advanced or metastatic non-small cell lung cancer.
Summit closed the previous session at $14.60 and opened at $15.52 on the Nasdaq. The stock has traded between $15.52 and $16.38, with volume at 4.27 million shares, compared with average volume of 5.17 million. Its 52-week range is $12.07 to $29.23.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
In a pre-planned analysis, the company's partner Akeso Inc. noted that ivonescimab monotherapy demonst...